Radiopharmaceutical developer Clarity Pharmaceuticals has reached 50% recruitment for its Phase II Copper-64 SAR-Bombesin in Biochemical REcurrence of Prostate Cancer (SABRE) trial.
Twenty-five out of 50 patients have been enrolled and imaged, according to the firm. The trial's primary objective is to assess the safety of its copper 64-labeled radiopharmaceutical and its ability to correctly detect prostate cancer recurrence.
